NeuroSense Therapeutics Ltd. — Operating Income by Fiscal Year
5 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/73a78f49-3684-4ba5-8cc5-375e3f68e3c0/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-11.1M | 2025-01-01 – 2025-12-31 | evidence 0001213900-26-036970 |
| FY 2024 | $-9.9M | 2024-01-01 – 2024-12-31 | evidence 0001213900-25-029464 |
| FY 2023 | $-12.0M | 2023-01-01 – 2023-12-31 | evidence 0001213900-24-053407 |
| FY 2022 | $-10.6M | 2022-01-01 – 2022-12-31 | evidence 0001213900-24-053407 |
| FY 2021 | $-3.0M | 2021-01-01 – 2021-12-31 | evidence 0001213900-24-053407 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).